Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
Apr 10 2024University of Texas M. D. Anderson Cancer Center Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
Previous work from Strati demonstrated that specific white blood cells known as SIRPα+ macrophages may mediate resistance to the R2 combination, leading to the hypothesis that adding evorpacept to the R2 combination could have synergistic results. Blocking CD47 prevents the 'don't eat me signal' that results from the interaction of SIRPα and CD47.
A Phase II study investigating the efficacy of this combination in previously untreated patients is now enrolling. Related StoriesOf the 41 patients able to be evaluated for response, SKB264 achieved an objective response rate of 22%, a disease control rate of 80.5%, and a median duration of response of 7.5 months.
Forty-eight patients were evaluable for safety, with a follow-up of at least nine weeks at the data cutoff. All received previous therapy, with 50% having received multiple prior lines of therapy. Treatment-related adverse events higher than grade 3 were seen in 52.1% of patients, with the most common being anemia, decreased white blood cell or neutrophil counts, and neutropenia. Only 18.8% of patients had to decrease dosage, and 33.3% had to delay dosing due to adverse events.
Of 22 patients able to be evaluated for efficacy, six achieved partial responses and two achieved stable disease for at least six months. Notably, a patient with advanced triple-negative breast cancer with PIK3CA H1047R, PTEN and ARID1A mutations achieved a confirmed radiological partial response and was on trial for 42 months with minimal side effects.
Anemia Antibody Antibody-Drug Conjugate Blood Cell Clinical Trial Efficacy Hodgkin Lymphoma Lymphoma Mutation Myeloma Neutropenia Non-Hodgkin Lymphoma Ph Research Rituximab Therapeutics
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
The Sims 4 University cheats – enroll in university, learn skills, and earn a degreeAre you looking for all the Sims 4 University cheats? Help you Sims survive college life and get a degree quickly.
続きを読む »
University of Cologne Identifies Mechanisms Governing Relapse in Small Cell Lung CancerA research team at the University of Cologne has identified the mechanisms governing relapse in small cell lung cancer (SCLC) for the first time. Therapy is typically efficacious at the beginning due to treatment-sensitive cancer cells, but other numerous and very different cancer cells are hidden within these populations.
続きを読む »
Cancer on campus: Over 150 students and staff at North Carolina university 'are diagnosed with host...More than 150 cancer cases have been linked to Poe Hall, a class building at North Carolina State University in Raleigh. Reports found high levels of the cancer-causing cehmicals PCBs.
続きを読む »
Eight-year-old cancer survivor supported by Princess of Wales saddened by her cancer announcementAn eight-year-old girl who overcame her cancer battle and was supported by the Princess of Wales 'is deeply saddened' by her recent cancer announcement, her mother has said. Mila, who was visited by Kate during the pandemic while she was undergoing treatment for cancer, will also reach out to the princess and offer her support.
続きを読む »
Inside the royals' cancer battles as Kate announces she is receiving treatment for cancerThe Princess of Wales has said she is receiving preventative chemotherapy after King Charles and Sarah Ferguson were diagnosed with forms of the disease earlier this year.
続きを読む »
Subtyping of breast cancer cell lines reveals insights into cancer-relevant genesCell lines are an important in vitro model in breast cancer research. A team around biochemist Dr. Sonja Eberth and bioinformatician Dr.
続きを読む »